SCHEMBL2905

SCHEMBL2905

COCC1CC[C@H](Nc2ccccc2)[C@]2(O)CCCOC12

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.37
HTT P42858 2/20 0.32
GAA P10253 2/20 0.31
ALDH1A1 P00352 2/20 0.31
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
HPGD P15428 4/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
SLC6A3 Q01959 2/20 0.31
KCNH3 Q9ULD8 1/20 0.31
NPC1 O15118 1/20 0.30
TP53 P04637 1/20 0.30
POLB P06746 1/20 0.30
RAB9A P51151 1/20 0.30
ALOX15 P16050 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14682 1.00 TRPA1 (0.37) TRPA1HTTGAAALDH1A1MAPT
SCHEMBL11954736 1.00 TRPA1 (0.37) TRPA1HTTGAAALDH1A1MAPT
SCHEMBL11954743 0.89 TRPA1 (0.47) TRPA1HTTALDH1A1MAPTSMN1; SMN2
SCHEMBL15827861 0.89 TRPA1 (0.47) TRPA1HTTALDH1A1MAPTSMN1; SMN2
SCHEMBL11895635 0.89 TRPA1 (0.47) TRPA1HTTALDH1A1MAPTSMN1; SMN2
SCHEMBL15810023 0.89 TRPA1 (0.47) TRPA1HTTALDH1A1MAPTSMN1; SMN2
SCHEMBL2906 0.89 TRPA1 (0.47) TRPA1HTTALDH1A1MAPTSMN1; SMN2
SCHEMBL11967096 0.89 TRPA1 (0.47) TRPA1HTTALDH1A1MAPTSMN1; SMN2
SCHEMBL14683 0.86 TRPA1 (0.40) TRPA1HTTGAAALDH1A1MAPT
SCHEMBL11954708 0.86 TRPA1 (0.40) TRPA1HTTGAAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2485737-B1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME (US) 2014-06-25 EP claimed
EP-2485737-A1 NOVEL TRPA1 ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2012-08-15 EP claimed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US claimed
WO-2011043954-A1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-04-14 WO claimed
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
EP-2485737-B1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME (US) 2014-06-25 EP disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS TRPA1, TRPV1, TRPV2 TRPA1 1/4885HTT 672/4885GAA 4627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.